ALIGOS Therapeutics

  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers

The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments

ALG-000184, Publications

The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments

Preclinical, Publications

Antisense oligonucleotide-based strategy to target hepatitis delta virus infections

Preclinical, Publications

A Syrian hamster model of persistent HDV infection

Preclinical, Publications

Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro

ALG-000184, Publications

Capsid assembly modulators bind and directly target HBeAg

Preclinical, Publications

PML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cells

Preclinical, Publications

Antisense oligonucleotides as drugs with both direct and indirect antiviral actions

ALG-097558, Publications

Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor

ALG-000184, Publications

European Association for the Study of the Liver Congress (EASL) 2025 Satellite Symposium Recording

ALG-055009, Publications

Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints 

US OFFICE
1 Corporate Dr., 2nd Floor
South San Francisco, CA 94080

EU OFFICE
Gaston Geenslaan 1 / (Building 3)
3001 Leuven, Belgium

CHINA OFFICE
Unit 3212, Building A, No. 100, Zunyi Road, Changning District, Shanghai, People’s Republic of China, 200051

FOLLOW US

info@aligos.com

© Aligos Therapeutics 2025

  • Privacy Policy
  • Terms of Service
MENU
  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers